Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHA:603896)
22.30
+0.02 (0.09%)
Jan 23, 2026, 3:00 PM CST
SHA:603896 Revenue
Zhejiang Shouxiangu Pharmaceutical had revenue of 130.45M CNY in the quarter ending September 30, 2025, with 8.51% growth. This brings the company's revenue in the last twelve months to 642.66M, down -10.85% year-over-year. In the year 2024, Zhejiang Shouxiangu Pharmaceutical had annual revenue of 691.68M, down -11.81%.
Revenue (ttm)
642.66M
Revenue Growth
-10.85%
P/S Ratio
6.87
Revenue / Employee
574.83K
Employees
1,118
Market Cap
4.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 691.68M | -92.66M | -11.81% |
| Dec 31, 2023 | 784.35M | -44.72M | -5.39% |
| Dec 31, 2022 | 829.07M | 61.93M | 8.07% |
| Dec 31, 2021 | 767.14M | 131.09M | 20.61% |
| Dec 31, 2020 | 636.05M | 89.29M | 16.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Qingdao Vland Biotech INC. | 1.39B |
| Beijing Kawin Technology Share-Holding | 1.15B |
| Pulike Biological Engineering | 1.10B |
| Boji Medical Technology | 770.19M |
| Innovita Biological Technology | 430.96M |
| Guanhao Biotech | 392.83M |
| Yantai Zhenghai Biotechnology | 347.60M |
| Shanghai Shen Lian Biomedical | 292.81M |